{"id":"intensified-tbm-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Ototoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tuberculous meningitis (TBM) is a severe form of tuberculosis affecting the brain and spinal cord membranes, with poor drug penetration across the blood-brain barrier being a major treatment challenge. Intensified regimens aim to achieve higher cerebrospinal fluid (CSF) concentrations of first-line anti-TB agents (isoniazid, rifampicin, pyrazinamide, ethambutol) through increased dosing or dosing frequency, thereby improving bacterial sterilization and clinical outcomes. This approach is being evaluated in phase 3 trials to establish optimal dosing strategies for this life-threatening infection.","oneSentence":"Intensified TBM treatment uses higher doses and/or more frequent administration of anti-tuberculous drugs to improve penetration into the central nervous system and enhance bacterial killing in tuberculous meningitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:38.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculous meningitis (TBM)"}]},"trialDetails":[{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT05917340","phase":"PHASE3","title":"Intensified Short Course Regimen for TBM in Adults","status":"NOT_YET_RECRUITING","sponsor":"Indian Council of Medical Research","startDate":"2024-03","conditions":"Tuberculous Meningitis","enrollment":372},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT03927313","phase":"PHASE2","title":"Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-06-12","conditions":"Tuberculosis Meningitis, HIV-1-infection","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intensified TBM treatment","genericName":"Intensified TBM treatment","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intensified TBM treatment uses higher doses and/or more frequent administration of anti-tuberculous drugs to improve penetration into the central nervous system and enhance bacterial killing in tuberculous meningitis. Used for Tuberculous meningitis (TBM).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}